 William Robinson
Concepts (766)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 89 | 2023 | 664 | 7.470 |
Why?
| | Skin Neoplasms | 44 | 2022 | 762 | 3.770 |
Why?
| | Proto-Oncogene Proteins c-kit | 6 | 2019 | 64 | 1.910 |
Why?
| | Mastocytosis | 3 | 2021 | 12 | 1.640 |
Why?
| | Antineoplastic Agents | 18 | 2021 | 1967 | 1.170 |
Why?
| | Mutation | 17 | 2022 | 3435 | 0.910 |
Why?
| | Antibodies, Monoclonal | 7 | 2018 | 1279 | 0.880 |
Why?
| | Osteoporotic Fractures | 2 | 2020 | 50 | 0.850 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.780 |
Why?
| | Piperazines | 7 | 2018 | 316 | 0.760 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2019 | 43 | 0.740 |
Why?
| | Middle Aged | 87 | 2022 | 27511 | 0.710 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2018 | 179 | 0.680 |
Why?
| | Exome | 2 | 2017 | 210 | 0.680 |
Why?
| | Spinal Fractures | 1 | 2020 | 77 | 0.680 |
Why?
| | Esophageal Achalasia | 1 | 2019 | 25 | 0.670 |
Why?
| | Histiocytosis, Sinus | 1 | 2018 | 7 | 0.640 |
Why?
| | Neurofibromin 1 | 2 | 2017 | 22 | 0.640 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 134 | 0.640 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2013 | 58 | 0.640 |
Why?
| | Humeral Head | 1 | 2017 | 14 | 0.630 |
Why?
| | Osteoporosis | 2 | 2020 | 226 | 0.630 |
Why?
| | Orthopedics | 1 | 2020 | 131 | 0.620 |
Why?
| | Arthroplasty, Replacement, Shoulder | 1 | 2017 | 24 | 0.620 |
Why?
| | Carcinoma, Merkel Cell | 2 | 2008 | 16 | 0.610 |
Why?
| | Intention | 1 | 2019 | 141 | 0.610 |
Why?
| | Humans | 188 | 2023 | 118257 | 0.610 |
Why?
| | Databases, Factual | 4 | 2020 | 1196 | 0.610 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 50 | 0.590 |
Why?
| | Vitiligo | 4 | 2020 | 75 | 0.580 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2020 | 202 | 0.580 |
Why?
| | Mucous Membrane | 1 | 2017 | 112 | 0.570 |
Why?
| | MicroRNAs | 4 | 2023 | 633 | 0.560 |
Why?
| | Genetic Predisposition to Disease | 4 | 2019 | 2262 | 0.560 |
Why?
| | Forecasting | 2 | 2017 | 348 | 0.550 |
Why?
| | Female | 110 | 2022 | 61262 | 0.540 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1056 | 0.540 |
Why?
| | Spinal Fusion | 1 | 2019 | 225 | 0.540 |
Why?
| | Shoulder Joint | 1 | 2017 | 174 | 0.530 |
Why?
| | Hematopoiesis | 22 | 1988 | 176 | 0.530 |
Why?
| | Aged | 62 | 2021 | 19594 | 0.530 |
Why?
| | Sentinel Lymph Node Biopsy | 7 | 2021 | 118 | 0.530 |
Why?
| | Osteoarthritis | 1 | 2017 | 178 | 0.520 |
Why?
| | Pyrimidines | 4 | 2008 | 382 | 0.520 |
Why?
| | Phosphoproteins | 1 | 2017 | 303 | 0.520 |
Why?
| | Neoplasms, Second Primary | 3 | 2023 | 93 | 0.520 |
Why?
| | Adult | 85 | 2021 | 31325 | 0.510 |
Why?
| | Aged, 80 and over | 21 | 2021 | 6541 | 0.510 |
Why?
| | Melanocytes | 5 | 2020 | 66 | 0.500 |
Why?
| | Granulocytes | 24 | 1988 | 77 | 0.490 |
Why?
| | Ultraviolet Therapy | 3 | 2020 | 20 | 0.470 |
Why?
| | Microphthalmia-Associated Transcription Factor | 3 | 2008 | 14 | 0.460 |
Why?
| | Nevus | 3 | 2010 | 25 | 0.460 |
Why?
| | Male | 89 | 2022 | 57476 | 0.460 |
Why?
| | Cell Line, Tumor | 17 | 2018 | 2837 | 0.450 |
Why?
| | Neoplastic Stem Cells | 5 | 2018 | 336 | 0.440 |
Why?
| | Milk, Human | 1 | 2014 | 134 | 0.440 |
Why?
| | Colony-Stimulating Factors | 19 | 1988 | 32 | 0.440 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 1385 | 0.420 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2012 | 25 | 0.420 |
Why?
| | Breast Neoplasms | 8 | 2017 | 1957 | 0.410 |
Why?
| | Pyrroles | 3 | 2021 | 188 | 0.400 |
Why?
| | Military Personnel | 1 | 2019 | 527 | 0.400 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1161 | 0.400 |
Why?
| | Triazines | 2 | 2021 | 39 | 0.390 |
Why?
| | Sulfonamides | 4 | 2020 | 444 | 0.390 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 61 | 0.380 |
Why?
| | Lymph Node Excision | 5 | 2021 | 158 | 0.380 |
Why?
| | Lymphatic Metastasis | 7 | 2013 | 306 | 0.370 |
Why?
| | Adenocarcinoma | 5 | 2016 | 807 | 0.370 |
Why?
| | Sentinel Lymph Node | 2 | 2021 | 40 | 0.370 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2023 | 57 | 0.370 |
Why?
| | Skin Pigmentation | 3 | 2020 | 43 | 0.370 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2018 | 449 | 0.350 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2020 | 21 | 0.340 |
Why?
| | RNA, Neoplasm | 2 | 2008 | 77 | 0.340 |
Why?
| | Immunohistochemistry | 6 | 2019 | 1681 | 0.330 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2022 | 156 | 0.330 |
Why?
| | Sarcoma, Clear Cell | 1 | 2008 | 6 | 0.330 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2008 | 17 | 0.320 |
Why?
| | Pyrazoles | 2 | 2021 | 363 | 0.320 |
Why?
| | Cyclins | 1 | 2008 | 79 | 0.320 |
Why?
| | Nitrophenols | 3 | 2017 | 31 | 0.310 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 41 | 0.310 |
Why?
| | Tretinoin | 4 | 2023 | 116 | 0.310 |
Why?
| | Genes, p16 | 2 | 2007 | 18 | 0.310 |
Why?
| | Biphenyl Compounds | 3 | 2017 | 52 | 0.310 |
Why?
| | Tamoxifen | 3 | 2016 | 198 | 0.290 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 317 | 0.290 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 29 | 0.290 |
Why?
| | GTP Phosphohydrolases | 4 | 2020 | 69 | 0.280 |
Why?
| | Tumor Suppressor Proteins | 3 | 2015 | 287 | 0.270 |
Why?
| | Interferon-alpha | 6 | 2006 | 191 | 0.270 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2018 | 737 | 0.270 |
Why?
| | Prognosis | 13 | 2023 | 3424 | 0.270 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 5 | 2021 | 225 | 0.270 |
Why?
| | Treatment Outcome | 11 | 2020 | 9319 | 0.270 |
Why?
| | Leukocytes | 12 | 1986 | 284 | 0.260 |
Why?
| | Follow-Up Studies | 12 | 2020 | 4574 | 0.260 |
Why?
| | DNA, Neoplasm | 5 | 2017 | 153 | 0.260 |
Why?
| | Liposarcoma | 1 | 2005 | 26 | 0.260 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2023 | 357 | 0.250 |
Why?
| | Polymerase Chain Reaction | 6 | 2008 | 1004 | 0.250 |
Why?
| | Piperidines | 2 | 2018 | 171 | 0.240 |
Why?
| | Lymph Nodes | 1 | 2006 | 443 | 0.240 |
Why?
| | Neoplasm Staging | 10 | 2019 | 1221 | 0.240 |
Why?
| | Melatonin | 3 | 1994 | 104 | 0.240 |
Why?
| | Exons | 3 | 2019 | 306 | 0.240 |
Why?
| | Dacarbazine | 7 | 2012 | 102 | 0.240 |
Why?
| | Mice, Nude | 4 | 2020 | 662 | 0.230 |
Why?
| | Hair Follicle | 3 | 2020 | 52 | 0.230 |
Why?
| | Stem Cells | 4 | 2017 | 556 | 0.230 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2016 | 671 | 0.230 |
Why?
| | Flavonoids | 1 | 2003 | 69 | 0.230 |
Why?
| | HLA-DR Antigens | 2 | 2022 | 223 | 0.220 |
Why?
| | Genes, erbB-1 | 2 | 2016 | 18 | 0.220 |
Why?
| | Chromosome Aberrations | 2 | 1994 | 136 | 0.220 |
Why?
| | Lysophospholipids | 1 | 2023 | 66 | 0.220 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2016 | 895 | 0.220 |
Why?
| | Hematopoietic Stem Cells | 11 | 1986 | 359 | 0.210 |
Why?
| | Registries | 3 | 2020 | 1806 | 0.210 |
Why?
| | Mastocytosis, Systemic | 1 | 2021 | 5 | 0.210 |
Why?
| | Mice | 25 | 2021 | 15446 | 0.210 |
Why?
| | Clone Cells | 7 | 2010 | 247 | 0.210 |
Why?
| | Risk Factors | 8 | 2020 | 8958 | 0.200 |
Why?
| | Burns | 6 | 1997 | 247 | 0.200 |
Why?
| | Genomics | 3 | 2022 | 668 | 0.200 |
Why?
| | Cell Cycle Proteins | 3 | 2007 | 563 | 0.200 |
Why?
| | Sonication | 1 | 2020 | 10 | 0.190 |
Why?
| | Drug Therapy, Combination | 5 | 2016 | 964 | 0.190 |
Why?
| | Transcription, Genetic | 5 | 2017 | 1322 | 0.190 |
Why?
| | Leukemia | 8 | 1988 | 208 | 0.190 |
Why?
| | Turner Syndrome | 1 | 2001 | 50 | 0.190 |
Why?
| | Adult Stem Cells | 1 | 2020 | 34 | 0.180 |
Why?
| | Laser Capture Microdissection | 2 | 2017 | 26 | 0.180 |
Why?
| | Aniline Compounds | 1 | 2020 | 70 | 0.180 |
Why?
| | Tissue Culture Techniques | 1 | 2020 | 66 | 0.180 |
Why?
| | Interleukin-1 | 2 | 2019 | 979 | 0.180 |
Why?
| | Thoracic Vertebrae | 1 | 2020 | 72 | 0.180 |
Why?
| | Tumor Cells, Cultured | 6 | 2003 | 871 | 0.180 |
Why?
| | beta Catenin | 2 | 2020 | 219 | 0.180 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 67 | 0.170 |
Why?
| | RNA | 2 | 2016 | 830 | 0.170 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 74 | 0.170 |
Why?
| | Nomograms | 1 | 2019 | 48 | 0.170 |
Why?
| | Sequence Analysis, RNA | 3 | 2018 | 410 | 0.170 |
Why?
| | Bone Density | 2 | 2020 | 447 | 0.170 |
Why?
| | Heart Neoplasms | 2 | 1999 | 50 | 0.170 |
Why?
| | Cervical Vertebrae | 1 | 2020 | 113 | 0.170 |
Why?
| | Signal Transduction | 7 | 2023 | 4688 | 0.170 |
Why?
| | Visual Analog Scale | 1 | 2019 | 31 | 0.170 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 43 | 0.170 |
Why?
| | Prostheses and Implants | 1 | 2020 | 142 | 0.170 |
Why?
| | Lumbosacral Region | 1 | 2019 | 50 | 0.170 |
Why?
| | Molecular Targeted Therapy | 2 | 2019 | 355 | 0.170 |
Why?
| | Animals | 29 | 2021 | 33152 | 0.170 |
Why?
| | Retrospective Studies | 13 | 2021 | 12929 | 0.170 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 27 | 0.170 |
Why?
| | Ipilimumab | 1 | 2018 | 29 | 0.160 |
Why?
| | Case-Control Studies | 5 | 2022 | 3156 | 0.160 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 61 | 0.160 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 214 | 0.160 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 695 | 0.160 |
Why?
| | Pedigree | 2 | 2019 | 485 | 0.160 |
Why?
| | Septins | 1 | 2018 | 40 | 0.160 |
Why?
| | Hospital Costs | 1 | 2018 | 110 | 0.160 |
Why?
| | Leukemia, Myeloid | 10 | 1984 | 42 | 0.160 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 21 | 0.160 |
Why?
| | Biofilms | 1 | 2020 | 231 | 0.160 |
Why?
| | Gene Expression Profiling | 4 | 2018 | 1590 | 0.160 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 64 | 0.150 |
Why?
| | Receptors, Androgen | 1 | 1998 | 132 | 0.150 |
Why?
| | Cisplatin | 4 | 2006 | 271 | 0.150 |
Why?
| | Ultraviolet Rays | 2 | 2022 | 381 | 0.150 |
Why?
| | Low Back Pain | 1 | 2019 | 100 | 0.150 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 186 | 0.150 |
Why?
| | Adenine | 1 | 2018 | 222 | 0.150 |
Why?
| | Databases, Genetic | 1 | 2018 | 215 | 0.150 |
Why?
| | Benzamides | 2 | 2008 | 176 | 0.150 |
Why?
| | Membrane Proteins | 4 | 2020 | 1048 | 0.150 |
Why?
| | Bone Marrow Cells | 16 | 1983 | 273 | 0.140 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 14 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2018 | 227 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 618 | 0.140 |
Why?
| | Brain Neoplasms | 4 | 1994 | 1019 | 0.140 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1994 | 92 | 0.140 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 224 | 0.140 |
Why?
| | Antigens, Neoplasm | 5 | 2005 | 228 | 0.140 |
Why?
| | Colony-Forming Units Assay | 18 | 1988 | 94 | 0.140 |
Why?
| | Preservation, Biological | 3 | 2014 | 7 | 0.140 |
Why?
| | Freezing | 4 | 2014 | 87 | 0.140 |
Why?
| | Pain Measurement | 1 | 2019 | 468 | 0.140 |
Why?
| | Bone Marrow Transplantation | 10 | 1986 | 244 | 0.140 |
Why?
| | Adolescent | 33 | 2020 | 18364 | 0.140 |
Why?
| | Protein Isoforms | 1 | 2017 | 345 | 0.140 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 77 | 0.140 |
Why?
| | Bone Marrow | 13 | 1983 | 252 | 0.140 |
Why?
| | Drug Synergism | 4 | 2018 | 338 | 0.140 |
Why?
| | Carrier Proteins | 2 | 2000 | 725 | 0.140 |
Why?
| | Lung Neoplasms | 7 | 2016 | 2216 | 0.140 |
Why?
| | Interferon Type I | 4 | 1994 | 129 | 0.140 |
Why?
| | Lentigo | 1 | 2015 | 5 | 0.130 |
Why?
| | Cell Cycle | 3 | 2010 | 547 | 0.130 |
Why?
| | Apoptosis | 4 | 2018 | 2461 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1124 | 0.130 |
Why?
| | Reoperation | 1 | 2017 | 557 | 0.130 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2006 | 60 | 0.130 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2014 | 134 | 0.130 |
Why?
| | Leukocyte Count | 20 | 1988 | 303 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 980 | 0.130 |
Why?
| | Lymphoma | 4 | 1991 | 179 | 0.130 |
Why?
| | Fenretinide | 1 | 2014 | 4 | 0.130 |
Why?
| | Myeloproliferative Disorders | 1 | 1995 | 25 | 0.130 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2018 | 247 | 0.130 |
Why?
| | Head and Neck Neoplasms | 3 | 2013 | 469 | 0.130 |
Why?
| | Radiography | 1 | 2017 | 860 | 0.130 |
Why?
| | Desiccation | 1 | 2014 | 17 | 0.130 |
Why?
| | Oligopeptides | 1 | 2016 | 250 | 0.130 |
Why?
| | Survival Analysis | 6 | 2010 | 1262 | 0.120 |
Why?
| | Cell Survival | 8 | 2018 | 1045 | 0.120 |
Why?
| | Cell Division | 11 | 1998 | 775 | 0.120 |
Why?
| | Peptides | 2 | 2008 | 879 | 0.120 |
Why?
| | Peptide Fragments | 1 | 2018 | 700 | 0.120 |
Why?
| | Perineum | 1 | 1993 | 29 | 0.120 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 386 | 0.120 |
Why?
| | Internet | 1 | 2018 | 602 | 0.120 |
Why?
| | Basigin | 1 | 2013 | 27 | 0.120 |
Why?
| | Ear, External | 1 | 2013 | 24 | 0.110 |
Why?
| | Mohs Surgery | 1 | 2013 | 25 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 1937 | 0.110 |
Why?
| | Cell Proliferation | 5 | 2018 | 2262 | 0.110 |
Why?
| | Extracellular Space | 1 | 2013 | 127 | 0.110 |
Why?
| | Sweat Gland Neoplasms | 1 | 2012 | 6 | 0.110 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 127 | 0.110 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1992 | 62 | 0.110 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1992 | 65 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2017 | 310 | 0.110 |
Why?
| | Decision Making | 1 | 2019 | 806 | 0.110 |
Why?
| | BRCA1 Protein | 1 | 2013 | 57 | 0.110 |
Why?
| | Alleles | 2 | 2022 | 829 | 0.110 |
Why?
| | Side-Population Cells | 1 | 2012 | 10 | 0.110 |
Why?
| | Vitamins | 1 | 1994 | 157 | 0.110 |
Why?
| | Bone Marrow Diseases | 3 | 1983 | 18 | 0.110 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 56 | 0.110 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 162 | 0.110 |
Why?
| | Ricin | 1 | 1991 | 8 | 0.100 |
Why?
| | Escherichia coli Infections | 4 | 1981 | 105 | 0.100 |
Why?
| | Child | 15 | 2020 | 19033 | 0.100 |
Why?
| | Sequence Analysis, DNA | 2 | 2005 | 748 | 0.100 |
Why?
| | Immunotoxins | 1 | 1991 | 35 | 0.100 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2659 | 0.100 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 610 | 0.100 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 379 | 0.100 |
Why?
| | Complement C1q | 1 | 2011 | 38 | 0.100 |
Why?
| | Neoplasms | 5 | 2018 | 2160 | 0.100 |
Why?
| | Immune Tolerance | 2 | 1991 | 330 | 0.100 |
Why?
| | Cyclosporine | 1 | 1991 | 173 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2006 | 1857 | 0.100 |
Why?
| | Pancreatitis | 1 | 1991 | 105 | 0.100 |
Why?
| | Agranulocytosis | 6 | 1986 | 31 | 0.090 |
Why?
| | Blast Crisis | 1 | 1990 | 19 | 0.090 |
Why?
| | Quality Improvement | 1 | 2018 | 962 | 0.090 |
Why?
| | Cohort Studies | 2 | 2019 | 5078 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 3043 | 0.090 |
Why?
| | Bacterial Infections | 4 | 1989 | 226 | 0.090 |
Why?
| | Vitamin E | 2 | 1994 | 115 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2433 | 0.090 |
Why?
| | Disease-Free Survival | 5 | 2019 | 649 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2013 | 685 | 0.090 |
Why?
| | Indium Radioisotopes | 1 | 1989 | 24 | 0.090 |
Why?
| | Neutrophils | 8 | 1988 | 1142 | 0.090 |
Why?
| | Cell Differentiation | 7 | 2015 | 1746 | 0.090 |
Why?
| | Recombinant Proteins | 7 | 1994 | 1302 | 0.090 |
Why?
| | Transforming Growth Factor beta | 3 | 2019 | 461 | 0.080 |
Why?
| | Inflammation | 1 | 2019 | 2545 | 0.080 |
Why?
| | Lithium | 5 | 1986 | 41 | 0.080 |
Why?
| | Cyclin D | 1 | 2008 | 6 | 0.080 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 665 | 0.080 |
Why?
| | ErbB Receptors | 2 | 2013 | 569 | 0.080 |
Why?
| | Computational Biology | 3 | 2019 | 541 | 0.080 |
Why?
| | Transcription Factors | 1 | 1996 | 1567 | 0.080 |
Why?
| | Cells, Cultured | 11 | 2019 | 4044 | 0.080 |
Why?
| | S Phase | 1 | 2008 | 74 | 0.080 |
Why?
| | Survival Rate | 7 | 2013 | 1716 | 0.080 |
Why?
| | Base Sequence | 2 | 2011 | 2148 | 0.080 |
Why?
| | Australia | 2 | 2023 | 212 | 0.080 |
Why?
| | Sequence Deletion | 1 | 2008 | 169 | 0.080 |
Why?
| | Receptor, Notch2 | 2 | 2020 | 14 | 0.080 |
Why?
| | Factor VIII | 1 | 1987 | 55 | 0.080 |
Why?
| | Up-Regulation | 3 | 2019 | 862 | 0.080 |
Why?
| | Glucuronidase | 1 | 2007 | 48 | 0.080 |
Why?
| | Oligosaccharides | 1 | 2007 | 47 | 0.080 |
Why?
| | Cell Movement | 5 | 2015 | 888 | 0.080 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2007 | 11 | 0.080 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 141 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 207 | 0.070 |
Why?
| | Disease Progression | 2 | 2013 | 2477 | 0.070 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 13 | 0.070 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 23 | 0.070 |
Why?
| | Cell Self Renewal | 2 | 2017 | 51 | 0.070 |
Why?
| | Vaccinia virus | 2 | 1998 | 30 | 0.070 |
Why?
| | Hemophilia A | 1 | 1987 | 69 | 0.070 |
Why?
| | Health Education | 1 | 1990 | 317 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2010 | 454 | 0.070 |
Why?
| | Chromosome Mapping | 1 | 2008 | 508 | 0.070 |
Why?
| | Neoadjuvant Therapy | 2 | 2006 | 333 | 0.070 |
Why?
| | Myelodysplastic Syndromes | 1 | 1988 | 118 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3169 | 0.070 |
Why?
| | Education, Medical | 1 | 1990 | 239 | 0.070 |
Why?
| | United States | 2 | 2020 | 12491 | 0.070 |
Why?
| | Time Factors | 13 | 2014 | 6368 | 0.070 |
Why?
| | Quinazolines | 1 | 2008 | 245 | 0.070 |
Why?
| | Binding Sites | 2 | 2008 | 1221 | 0.070 |
Why?
| | Immunotherapy, Adoptive | 2 | 1998 | 191 | 0.070 |
Why?
| | Infant | 2 | 2019 | 8254 | 0.070 |
Why?
| | Spinal Cord Compression | 1 | 1985 | 18 | 0.070 |
Why?
| | Hypercalcemia | 1 | 1985 | 22 | 0.070 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 143 | 0.070 |
Why?
| | Genome, Human | 1 | 2008 | 381 | 0.070 |
Why?
| | Diphosphonates | 1 | 2006 | 50 | 0.070 |
Why?
| | Vena Cava, Superior | 1 | 1985 | 21 | 0.070 |
Why?
| | Viral Vaccines | 2 | 1998 | 89 | 0.070 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1343 | 0.070 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 504 | 0.070 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2005 | 23 | 0.070 |
Why?
| | Lymphocytes | 5 | 2006 | 346 | 0.070 |
Why?
| | Neoplasm Invasiveness | 3 | 2018 | 460 | 0.070 |
Why?
| | Kidney Transplantation | 1 | 1991 | 576 | 0.070 |
Why?
| | Testicular Neoplasms | 2 | 1984 | 95 | 0.070 |
Why?
| | In Vitro Techniques | 5 | 2012 | 1082 | 0.060 |
Why?
| | Karyotyping | 4 | 1994 | 102 | 0.060 |
Why?
| | Models, Biological | 3 | 2019 | 1701 | 0.060 |
Why?
| | Axilla | 1 | 2004 | 56 | 0.060 |
Why?
| | Acute Disease | 6 | 1991 | 933 | 0.060 |
Why?
| | Protein Transport | 2 | 2018 | 407 | 0.060 |
Why?
| | Neoplasm Metastasis | 4 | 2007 | 541 | 0.060 |
Why?
| | Blood Cell Count | 5 | 1995 | 52 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2004 | 195 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 108 | 0.060 |
Why?
| | Phosphorylation | 2 | 2018 | 1622 | 0.060 |
Why?
| | Genetic Testing | 1 | 2007 | 388 | 0.060 |
Why?
| | Macrophages | 3 | 1988 | 1311 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2057 | 0.060 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 51 | 0.060 |
Why?
| | Urine | 4 | 1973 | 58 | 0.060 |
Why?
| | Age Distribution | 2 | 2018 | 358 | 0.060 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 22 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 384 | 0.060 |
Why?
| | Inhibitory Concentration 50 | 1 | 2003 | 81 | 0.060 |
Why?
| | Schistosoma | 1 | 1983 | 18 | 0.060 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 29 | 0.060 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1983 | 58 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 102 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 808 | 0.060 |
Why?
| | Glycoproteins | 4 | 1977 | 317 | 0.060 |
Why?
| | Neutropenia | 3 | 1980 | 131 | 0.060 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2855 | 0.060 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 86 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 1984 | 268 | 0.050 |
Why?
| | Young Adult | 4 | 2020 | 10731 | 0.050 |
Why?
| | Smoking | 1 | 1990 | 1478 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 8 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2018 | 3676 | 0.050 |
Why?
| | Clinical Trials as Topic | 4 | 2018 | 964 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 47 | 0.050 |
Why?
| | Incidence | 3 | 2009 | 2413 | 0.050 |
Why?
| | Antigens | 2 | 1983 | 319 | 0.050 |
Why?
| | Leukocytosis | 4 | 1974 | 34 | 0.050 |
Why?
| | Isotretinoin | 2 | 1994 | 22 | 0.050 |
Why?
| | PAX3 Transcription Factor | 2 | 2015 | 12 | 0.050 |
Why?
| | Bone Neoplasms | 1 | 1983 | 198 | 0.050 |
Why?
| | Paired Box Transcription Factors | 2 | 2015 | 40 | 0.050 |
Why?
| | Gene Expression | 3 | 2008 | 1482 | 0.050 |
Why?
| | Smallpox Vaccine | 2 | 1998 | 23 | 0.050 |
Why?
| | Eosinophils | 1 | 1983 | 282 | 0.050 |
Why?
| | Administration, Oral | 5 | 1995 | 753 | 0.050 |
Why?
| | Urinary Bladder Neoplasms | 1 | 1983 | 211 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2000 | 14 | 0.050 |
Why?
| | Leukemia, Myeloid, Acute | 4 | 1984 | 532 | 0.050 |
Why?
| | Leukemia, Lymphoid | 6 | 1979 | 27 | 0.050 |
Why?
| | Enterobacter cloacae | 1 | 2020 | 3 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2003 | 523 | 0.050 |
Why?
| | Mycobacterium chelonae | 1 | 2020 | 8 | 0.050 |
Why?
| | Gene Amplification | 1 | 2020 | 97 | 0.050 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 50 | 0.050 |
Why?
| | Tetracycline | 1 | 2000 | 13 | 0.050 |
Why?
| | Tocopherols | 2 | 1994 | 20 | 0.050 |
Why?
| | Escherichia coli | 2 | 1983 | 757 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 110 | 0.050 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 64 | 0.050 |
Why?
| | Chromosomes, Human, 6-12 and X | 2 | 1994 | 3 | 0.050 |
Why?
| | Gene Dosage | 1 | 2020 | 135 | 0.050 |
Why?
| | Oxidoreductases | 1 | 2020 | 98 | 0.050 |
Why?
| | RNA, Messenger | 3 | 2019 | 2657 | 0.040 |
Why?
| | Monocytes | 3 | 1983 | 511 | 0.040 |
Why?
| | Data Curation | 1 | 2019 | 12 | 0.040 |
Why?
| | Germ-Free Life | 1 | 1979 | 30 | 0.040 |
Why?
| | Endotoxins | 2 | 1978 | 234 | 0.040 |
Why?
| | Vincristine | 3 | 1984 | 99 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 965 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 817 | 0.040 |
Why?
| | Mast Cells | 1 | 2020 | 115 | 0.040 |
Why?
| | Cyclophosphamide | 3 | 1983 | 222 | 0.040 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
| | Aneuploidy | 2 | 1994 | 88 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2019 | 86 | 0.040 |
Why?
| | Injections, Subcutaneous | 5 | 2007 | 139 | 0.040 |
Why?
| | Keratinocytes | 1 | 2020 | 227 | 0.040 |
Why?
| | Erythropoietin | 3 | 1982 | 82 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 29 | 0.040 |
Why?
| | Dynamins | 1 | 2018 | 30 | 0.040 |
Why?
| | Oncostatin M | 1 | 1998 | 5 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 1 | 1999 | 89 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 443 | 0.040 |
Why?
| | Chromosome Deletion | 2 | 1994 | 95 | 0.040 |
Why?
| | Heterografts | 1 | 2018 | 129 | 0.040 |
Why?
| | Bone Density Conservation Agents | 1 | 2018 | 61 | 0.040 |
Why?
| | Levamisole | 1 | 1977 | 20 | 0.040 |
Why?
| | Phenotype | 3 | 2015 | 2937 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 533 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 77 | 0.040 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2017 | 38 | 0.040 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 189 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2019 | 355 | 0.040 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.040 |
Why?
| | Sex Distribution | 1 | 2018 | 347 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2018 | 120 | 0.040 |
Why?
| | Drug Evaluation | 4 | 1991 | 81 | 0.040 |
Why?
| | Precancerous Conditions | 1 | 1998 | 160 | 0.040 |
Why?
| | Felty Syndrome | 4 | 1980 | 4 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 104 | 0.040 |
Why?
| | Anesthesia | 1 | 2018 | 120 | 0.040 |
Why?
| | Pharmacogenetics | 1 | 2018 | 149 | 0.040 |
Why?
| | Genes, p53 | 1 | 1997 | 64 | 0.040 |
Why?
| | CD146 Antigen | 1 | 2016 | 41 | 0.040 |
Why?
| | Thioguanine | 2 | 1984 | 20 | 0.040 |
Why?
| | Carmustine | 3 | 1986 | 47 | 0.040 |
Why?
| | Menopause | 2 | 2006 | 266 | 0.040 |
Why?
| | Cicatrix | 1 | 1997 | 53 | 0.040 |
Why?
| | MCF-7 Cells | 1 | 2016 | 110 | 0.040 |
Why?
| | Cytarabine | 2 | 1984 | 53 | 0.040 |
Why?
| | Thrombocytopenia | 4 | 2007 | 184 | 0.040 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 76 | 0.040 |
Why?
| | Splenomegaly | 2 | 1995 | 16 | 0.030 |
Why?
| | Cancer Vaccines | 1 | 1997 | 139 | 0.030 |
Why?
| | Hodgkin Disease | 4 | 1985 | 119 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2003 | 939 | 0.030 |
Why?
| | Vinblastine | 2 | 2006 | 68 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 1998 | 1163 | 0.030 |
Why?
| | Interleukin-2 | 3 | 2006 | 416 | 0.030 |
Why?
| | Drug Administration Schedule | 4 | 2007 | 734 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 143 | 0.030 |
Why?
| | Mercaptopurine | 2 | 1972 | 15 | 0.030 |
Why?
| | Protein Binding | 2 | 2018 | 1969 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 1995 | 17 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 162 | 0.030 |
Why?
| | Gene Deletion | 1 | 1997 | 359 | 0.030 |
Why?
| | Inpatients | 1 | 2018 | 387 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2015 | 59 | 0.030 |
Why?
| | Veins | 1 | 1995 | 59 | 0.030 |
Why?
| | Primary Myelofibrosis | 1 | 1974 | 9 | 0.030 |
Why?
| | Polycythemia Vera | 1 | 1974 | 13 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 1995 | 379 | 0.030 |
Why?
| | Retinoids | 1 | 2014 | 32 | 0.030 |
Why?
| | Surgeons | 1 | 2018 | 242 | 0.030 |
Why?
| | Genetic Linkage | 1 | 2015 | 321 | 0.030 |
Why?
| | Culture Techniques | 4 | 1979 | 81 | 0.030 |
Why?
| | Random Allocation | 3 | 1990 | 344 | 0.030 |
Why?
| | Proteinuria | 1 | 1974 | 99 | 0.030 |
Why?
| | Epidermis | 1 | 2015 | 152 | 0.030 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 1994 | 3 | 0.030 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 1994 | 18 | 0.030 |
Why?
| | beta Carotene | 1 | 1994 | 17 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 1994 | 26 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1405 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 1993 | 11 | 0.030 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 1994 | 51 | 0.030 |
Why?
| | Vulvar Neoplasms | 1 | 1993 | 10 | 0.030 |
Why?
| | Carotenoids | 1 | 1994 | 35 | 0.030 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1994 | 33 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 1995 | 95 | 0.030 |
Why?
| | Vitamin B 12 | 1 | 1974 | 114 | 0.030 |
Why?
| | Estrogens | 1 | 2016 | 329 | 0.030 |
Why?
| | Anus Neoplasms | 1 | 1993 | 24 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 1994 | 89 | 0.030 |
Why?
| | Specimen Handling | 1 | 2014 | 163 | 0.030 |
Why?
| | Administration, Intranasal | 3 | 1989 | 79 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2016 | 453 | 0.030 |
Why?
| | Gonanes | 1 | 2013 | 28 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 1994 | 303 | 0.030 |
Why?
| | Feedback, Physiological | 1 | 2013 | 74 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1994 | 188 | 0.030 |
Why?
| | Ascorbic Acid | 1 | 1994 | 120 | 0.030 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 38 | 0.030 |
Why?
| | Iron | 3 | 1989 | 247 | 0.030 |
Why?
| | Epithelial Cells | 1 | 1998 | 951 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 64 | 0.030 |
Why?
| | Anemia, Aplastic | 3 | 1983 | 30 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 40 | 0.030 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 32 | 0.030 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 121 | 0.030 |
Why?
| | Cetuximab | 1 | 2013 | 99 | 0.030 |
Why?
| | Individuality | 1 | 1994 | 148 | 0.030 |
Why?
| | Flow Cytometry | 3 | 2008 | 1072 | 0.030 |
Why?
| | Pathology, Clinical | 1 | 2012 | 31 | 0.030 |
Why?
| | Patient Discharge | 1 | 2018 | 791 | 0.030 |
Why?
| | Mechlorethamine | 3 | 1982 | 58 | 0.030 |
Why?
| | Benzoates | 1 | 1972 | 40 | 0.030 |
Why?
| | Response Elements | 1 | 2012 | 82 | 0.030 |
Why?
| | Precision Medicine | 1 | 2016 | 354 | 0.030 |
Why?
| | Coloring Agents | 1 | 2012 | 72 | 0.030 |
Why?
| | Vaccines | 1 | 1997 | 380 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 245 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 4887 | 0.030 |
Why?
| | Hawaii | 1 | 1991 | 37 | 0.030 |
Why?
| | Gene Silencing | 1 | 2012 | 177 | 0.030 |
Why?
| | Mice, SCID | 1 | 2012 | 331 | 0.030 |
Why?
| | Mitosis | 1 | 1992 | 172 | 0.030 |
Why?
| | Isoenzymes | 1 | 2012 | 297 | 0.030 |
Why?
| | Prednisone | 1 | 1972 | 235 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 240 | 0.020 |
Why?
| | Melphalan | 3 | 1986 | 30 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 193 | 0.020 |
Why?
| | Dermatology | 1 | 2012 | 88 | 0.020 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2010 | 22 | 0.020 |
Why?
| | DNA Repair | 1 | 2013 | 197 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 341 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 572 | 0.020 |
Why?
| | Sex Ratio | 1 | 1990 | 14 | 0.020 |
Why?
| | Megakaryocytes | 2 | 1981 | 29 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 1994 | 394 | 0.020 |
Why?
| | Pigmentation | 1 | 2010 | 57 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 356 | 0.020 |
Why?
| | California | 1 | 1991 | 370 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 146 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 562 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1186 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 532 | 0.020 |
Why?
| | Penicillin V | 1 | 1989 | 3 | 0.020 |
Why?
| | Body Surface Area | 1 | 2009 | 28 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2010 | 147 | 0.020 |
Why?
| | Deferoxamine | 1 | 1989 | 16 | 0.020 |
Why?
| | Imidazoles | 1 | 2010 | 227 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2010 | 151 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1379 | 0.020 |
Why?
| | Mouth | 1 | 1989 | 74 | 0.020 |
Why?
| | Lithium Chloride | 2 | 1986 | 13 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1989 | 124 | 0.020 |
Why?
| | Colorado | 2 | 2009 | 4178 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 764 | 0.020 |
Why?
| | Anemia | 2 | 1982 | 145 | 0.020 |
Why?
| | Abdomen | 1 | 2009 | 110 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 20 | 0.020 |
Why?
| | Temperature | 3 | 1981 | 621 | 0.020 |
Why?
| | Eye Color | 1 | 1988 | 4 | 0.020 |
Why?
| | Upper Extremity | 1 | 2009 | 81 | 0.020 |
Why?
| | Hair Color | 1 | 1988 | 11 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 1971 | 214 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 82 | 0.020 |
Why?
| | Age Factors | 3 | 1990 | 2990 | 0.020 |
Why?
| | Cimetidine | 1 | 1988 | 16 | 0.020 |
Why?
| | Chlorides | 2 | 1986 | 137 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 135 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 524 | 0.020 |
Why?
| | Liver Neoplasms | 2 | 2006 | 526 | 0.020 |
Why?
| | Contusions | 1 | 2007 | 21 | 0.020 |
Why?
| | Nausea | 1 | 2007 | 107 | 0.020 |
Why?
| | Leukopenia | 2 | 1991 | 26 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 151 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 12 | 0.020 |
Why?
| | Molecular Weight | 2 | 1979 | 340 | 0.020 |
Why?
| | Laparotomy | 1 | 2007 | 105 | 0.020 |
Why?
| | Vaccines, Combined | 2 | 1997 | 46 | 0.020 |
Why?
| | Prospective Studies | 4 | 2005 | 6443 | 0.020 |
Why?
| | Hydroxyurea | 2 | 1984 | 30 | 0.020 |
Why?
| | Hemoglobins | 1 | 1988 | 318 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2005 | 6 | 0.020 |
Why?
| | MART-1 Antigen | 1 | 2005 | 9 | 0.020 |
Why?
| | Double-Blind Method | 3 | 1998 | 1683 | 0.020 |
Why?
| | Tomography, Emission-Computed | 1 | 1986 | 58 | 0.020 |
Why?
| | Culture Media | 4 | 1977 | 161 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 817 | 0.020 |
Why?
| | Intestine, Small | 1 | 2007 | 130 | 0.020 |
Why?
| | Lower Extremity | 1 | 2009 | 334 | 0.020 |
Why?
| | Metaproterenol | 1 | 1985 | 2 | 0.020 |
Why?
| | Fatigue | 1 | 2007 | 293 | 0.020 |
Why?
| | Antigens, CD | 1 | 2008 | 457 | 0.020 |
Why?
| | Erythrocytes | 3 | 1981 | 619 | 0.020 |
Why?
| | Extremities | 1 | 2006 | 112 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 1988 | 322 | 0.020 |
Why?
| | Blood Platelets | 3 | 1974 | 344 | 0.020 |
Why?
| | Platelet Count | 2 | 1986 | 81 | 0.020 |
Why?
| | Neoplasm Proteins | 2 | 2005 | 398 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 840 | 0.020 |
Why?
| | Survivors | 1 | 2008 | 411 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2008 | 442 | 0.020 |
Why?
| | Spleen | 2 | 1981 | 504 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 1985 | 204 | 0.020 |
Why?
| | Nucleoproteins | 1 | 1984 | 27 | 0.020 |
Why?
| | Syndrome | 1 | 1985 | 343 | 0.020 |
Why?
| | Remission Induction | 2 | 1995 | 246 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2009 | 667 | 0.020 |
Why?
| | Emergencies | 1 | 1985 | 152 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 360 | 0.020 |
Why?
| | Administration, Topical | 1 | 1984 | 141 | 0.020 |
Why?
| | Podophyllotoxin | 1 | 1984 | 7 | 0.020 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 69 | 0.020 |
Why?
| | Epinephrine | 1 | 1985 | 166 | 0.020 |
Why?
| | Neuropilin-1 | 1 | 2003 | 9 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 149 | 0.010 |
Why?
| | Heart Arrest | 2 | 1984 | 291 | 0.010 |
Why?
| | Fibula | 1 | 1983 | 40 | 0.010 |
Why?
| | Cell Nucleolus | 1 | 1983 | 17 | 0.010 |
Why?
| | Enterobacter | 1 | 1983 | 7 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 1983 | 56 | 0.010 |
Why?
| | Busulfan | 1 | 1982 | 14 | 0.010 |
Why?
| | Klebsiella pneumoniae | 1 | 1983 | 39 | 0.010 |
Why?
| | Cell Nucleus | 2 | 1984 | 577 | 0.010 |
Why?
| | Erythropoiesis | 1 | 1982 | 33 | 0.010 |
Why?
| | Bleomycin | 1 | 1984 | 228 | 0.010 |
Why?
| | Cytoplasm | 1 | 1983 | 269 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 401 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1982 | 158 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 714 | 0.010 |
Why?
| | Transplantation, Autologous | 4 | 1984 | 191 | 0.010 |
Why?
| | Schistosomiasis | 1 | 1982 | 38 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 2855 | 0.010 |
Why?
| | Pain | 1 | 2007 | 736 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 940 | 0.010 |
Why?
| | Glycogen Storage Disease Type I | 1 | 1980 | 4 | 0.010 |
Why?
| | Choriocarcinoma | 1 | 1981 | 9 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2001 | 189 | 0.010 |
Why?
| | Pregnancy | 2 | 2004 | 5671 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1078 | 0.010 |
Why?
| | Thymidine Kinase | 1 | 2000 | 14 | 0.010 |
Why?
| | Pseudomonas aeruginosa | 1 | 1983 | 309 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2000 | 52 | 0.010 |
Why?
| | Blood Transfusion | 2 | 1974 | 278 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1980 | 124 | 0.010 |
Why?
| | Doxycycline | 1 | 2000 | 59 | 0.010 |
Why?
| | Luciferases | 1 | 2000 | 142 | 0.010 |
Why?
| | Chromosomes, Human, 4-5 | 1 | 1979 | 1 | 0.010 |
Why?
| | Anemia, Macrocytic | 1 | 1979 | 4 | 0.010 |
Why?
| | Thrombocytosis | 1 | 1979 | 7 | 0.010 |
Why?
| | Simplexvirus | 1 | 2000 | 86 | 0.010 |
Why?
| | Electrophoresis, Cellulose Acetate | 1 | 1979 | 1 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 126 | 0.010 |
Why?
| | Pronase | 1 | 1979 | 4 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1979 | 21 | 0.010 |
Why?
| | Sepsis | 1 | 1985 | 531 | 0.010 |
Why?
| | Ribonucleases | 1 | 1979 | 53 | 0.010 |
Why?
| | Trypsin | 1 | 1979 | 72 | 0.010 |
Why?
| | Autoantibodies | 2 | 1984 | 1334 | 0.010 |
Why?
| | Plasmids | 1 | 2000 | 355 | 0.010 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 1979 | 41 | 0.010 |
Why?
| | Remission, Spontaneous | 2 | 1977 | 37 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 3 | 1984 | 409 | 0.010 |
Why?
| | Hematocrit | 2 | 1977 | 89 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 1977 | 3 | 0.010 |
Why?
| | Hypocalcemia | 3 | 1984 | 30 | 0.010 |
Why?
| | Nitrogen | 1 | 1979 | 154 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 887 | 0.010 |
Why?
| | Species Specificity | 1 | 1979 | 559 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1979 | 528 | 0.010 |
Why?
| | Agar | 1 | 1977 | 12 | 0.010 |
Why?
| | Trans-Activators | 1 | 2000 | 373 | 0.010 |
Why?
| | Pneumonia | 1 | 1983 | 579 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 2 | 1983 | 990 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 650 | 0.010 |
Why?
| | Pericardium | 1 | 1976 | 50 | 0.010 |
Why?
| | Groin | 1 | 1995 | 16 | 0.010 |
Why?
| | Subclavian Vein | 1 | 1995 | 22 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1975 | 7 | 0.010 |
Why?
| | Patient Compliance | 2 | 1989 | 532 | 0.010 |
Why?
| | Typhoid-Paratyphoid Vaccines | 1 | 1975 | 4 | 0.010 |
Why?
| | Pyrogens | 1 | 1975 | 55 | 0.010 |
Why?
| | Iron Radioisotopes | 1 | 1974 | 3 | 0.010 |
Why?
| | Cobalt Radioisotopes | 1 | 1974 | 6 | 0.010 |
Why?
| | Pyelonephritis | 1 | 1974 | 8 | 0.010 |
Why?
| | Dialysis | 1 | 1974 | 24 | 0.010 |
Why?
| | Hospitals, University | 1 | 1995 | 172 | 0.010 |
Why?
| | Centrifugation | 1 | 1974 | 31 | 0.010 |
Why?
| | Salmonella | 1 | 1975 | 54 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1995 | 113 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 1994 | 28 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 93 | 0.010 |
Why?
| | Photoperiod | 1 | 1994 | 55 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1981 | 1770 | 0.010 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1974 | 81 | 0.010 |
Why?
| | Virus Diseases | 1 | 1976 | 197 | 0.010 |
Why?
| | Multiple Myeloma | 1 | 1974 | 100 | 0.010 |
Why?
| | Hydrocortisone | 1 | 1975 | 272 | 0.010 |
Why?
| | Procarbazine | 1 | 1972 | 8 | 0.010 |
Why?
| | Asthma | 1 | 1985 | 2143 | 0.010 |
Why?
| | Diseases in Twins | 1 | 1973 | 181 | 0.010 |
Why?
| | Doxorubicin | 2 | 1984 | 301 | 0.010 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1972 | 72 | 0.010 |
Why?
| | Drug Combinations | 1 | 1972 | 291 | 0.010 |
Why?
| | Length of Stay | 1 | 1995 | 1027 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2435 | 0.010 |
Why?
| | Perfusion | 1 | 1970 | 152 | 0.010 |
Why?
| | Taurodeoxycholic Acid | 1 | 1989 | 1 | 0.010 |
Why?
| | Skin | 1 | 1994 | 657 | 0.010 |
Why?
| | Mouth Mucosa | 1 | 1989 | 81 | 0.010 |
Why?
| | Debridement | 1 | 1989 | 79 | 0.010 |
Why?
| | Ferritins | 1 | 1989 | 59 | 0.010 |
Why?
| | Placebos | 1 | 1989 | 202 | 0.010 |
Why?
| | Antibody Formation | 1 | 1970 | 275 | 0.010 |
Why?
| | Bone Marrow Examination | 2 | 1979 | 7 | 0.010 |
Why?
| | Wounds and Injuries | 1 | 1995 | 697 | 0.000 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1985 | 36 | 0.000 |
Why?
| | Prostaglandins E | 1 | 1985 | 47 | 0.000 |
Why?
| | Saudi Arabia | 1 | 1985 | 6 | 0.000 |
Why?
| | Lactoferrin | 1 | 1985 | 28 | 0.000 |
Why?
| | Immunodiffusion | 1 | 1984 | 9 | 0.000 |
Why?
| | Polysaccharides, Bacterial | 1 | 1985 | 69 | 0.000 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1984 | 55 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2230 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1984 | 90 | 0.000 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1984 | 2 | 0.000 |
Why?
| | Teniposide | 1 | 1984 | 3 | 0.000 |
Why?
| | Tissue Preservation | 1 | 1984 | 12 | 0.000 |
Why?
| | Daunorubicin | 1 | 1984 | 23 | 0.000 |
Why?
| | Melanoma-Specific Antigens | 1 | 1983 | 2 | 0.000 |
Why?
| | Syncope | 1 | 1984 | 32 | 0.000 |
Why?
| | Aerosols | 1 | 1985 | 221 | 0.000 |
Why?
| | False Negative Reactions | 1 | 1983 | 57 | 0.000 |
Why?
| | Cell Line | 2 | 1983 | 2693 | 0.000 |
Why?
| | Lomustine | 1 | 1982 | 14 | 0.000 |
Why?
| | Phosphates | 1 | 1984 | 166 | 0.000 |
Why?
| | Heterozygote | 1 | 1983 | 260 | 0.000 |
Why?
| | Egypt | 1 | 1982 | 10 | 0.000 |
Why?
| | Fever | 1 | 1984 | 283 | 0.000 |
Why?
| | Heart Rate | 1 | 1985 | 729 | 0.000 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1981 | 197 | 0.000 |
Why?
| | Mice, Inbred Strains | 1 | 1981 | 404 | 0.000 |
Why?
| | Tachycardia | 1 | 1981 | 48 | 0.000 |
Why?
| | Cell Separation | 1 | 1981 | 293 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 353 | 0.000 |
Why?
| | Fanconi Anemia | 1 | 1979 | 12 | 0.000 |
Why?
| | Blood Cells | 1 | 1979 | 39 | 0.000 |
Why?
| | Complement System Proteins | 1 | 1981 | 290 | 0.000 |
Why?
| | Blood Pressure | 1 | 1985 | 1656 | 0.000 |
Why?
| | Cold Temperature | 1 | 1979 | 130 | 0.000 |
Why?
| | Electrocardiography | 1 | 1981 | 555 | 0.000 |
Why?
| | Pericardial Effusion | 1 | 1976 | 18 | 0.000 |
Why?
| | Blood | 1 | 1977 | 97 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1982 | 514 | 0.000 |
Why?
| | Autopsy | 1 | 1976 | 89 | 0.000 |
Why?
| | Cell Count | 1 | 1977 | 315 | 0.000 |
Why?
| | DNA | 1 | 1983 | 1385 | 0.000 |
Why?
| | Alpha-Globulins | 1 | 1975 | 20 | 0.000 |
Why?
| | Child, Preschool | 2 | 1980 | 9448 | 0.000 |
Why?
| | Recurrence | 1 | 1977 | 971 | 0.000 |
Why?
| | Cytogenetics | 1 | 1973 | 10 | 0.000 |
Why?
| | Periodicity | 1 | 1973 | 56 | 0.000 |
Why?
| | Muramidase | 1 | 1973 | 72 | 0.000 |
Why?
| | Arm | 1 | 1972 | 106 | 0.000 |
Why?
| | Chronic Disease | 1 | 1977 | 1630 | 0.000 |
Why?
| | Leg | 1 | 1972 | 234 | 0.000 |
Why?
| | Splenectomy | 1 | 1970 | 56 | 0.000 |
Why?
| | Immunity | 1 | 1970 | 129 | 0.000 |
Why?
| | Sheep | 1 | 1970 | 762 | 0.000 |
Why?
| | Swine | 1 | 1970 | 719 | 0.000 |
Why?
| | Immunization | 1 | 1970 | 412 | 0.000 |
Why?
|
|
Robinson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|